A Single Arm, Open Label, Multicenter, Phase II Study of Famitinib in Patients With Gastrointestinal Stromal Tumor
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2018
At a glance
- Drugs Famitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 04 Jan 2018 Last checked against ClinicalTrials.gov record.
- 01 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2016, according to ClinicalTrials.gov record.
- 01 Feb 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.